SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes
MWN-AI** Summary
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS), a late-stage clinical biopharmaceutical company specializing in innovative cancer therapies, has announced its inclusion in both the Russell 3000® and Russell 2000® indexes, effective June 27, 2025. This inclusion is a significant milestone for SELLAS, affirming the company's ongoing progress in advancing its therapeutic pipeline and enhancing shareholder value. The Russell 3000® index, which includes the top 3,000 publicly traded U.S. companies, serves as a vital benchmark for the U.S. equity market, while the Russell 2000® focuses on smaller-cap stocks, representing about 10% of total U.S. market capitalization.
SELLAS’ lead product candidate, GPS, targets the WT1 protein and holds promise as a treatment for various hematologic malignancies and solid tumors. Furthermore, the company is advancing SLS009 (tambiciclib), a potentially first-in-class CDK9 inhibitor demonstrating a high response rate in acute myeloid leukemia (AML) patients, particularly those with unfavorable prognoses. The acknowledgment by the Russell indexes is expected to increase SELLAS’ visibility amongst institutional investors, particularly as the company nears the release of critical Phase 2 data for SLS009 and completes the final analysis of its Phase 3 REGAL trial for GPS in AML.
John Burns, Senior Vice President and CFO, expressed optimism about the company’s trajectory following this index inclusion, as it is positioned to attract greater institutional interest. The forthcoming clinical milestones are anticipated to play a critical role in SELLAS' growth in the biopharmaceutical landscape. For more information about SELLAS and its endeavors, visit their website at www.sellaslifesciences.com.
MWN-AI** Analysis
SELLAS Life Sciences Group, Inc. has recently announced its inclusion in the Russell 3000 and Russell 2000 Indexes, effective June 27, 2025. This is a significant milestone for the company, marking its growing reputation in the biotechnology sector focused on cancer therapeutics. Market participants should consider this development as a precursor to increased visibility and investment potential.
Inclusion in these benchmarks is crucial, as it typically leads to enhanced liquidity and interest from institutional investors who track Russell indexes. Such attention can foster positive price momentum, particularly as SELLAS approaches critical clinical readouts of its product candidates, SLS009 and GPS. SLS009, characterized as a potentially best-in-class CDK9 inhibitor, shows promise, particularly in acute myeloid leukemia (AML), a sector with substantial unmet medical needs. The anticipated results from the ongoing Phase 2 and Phase 3 trials could confirm SLS009’s efficacy and safety profile, making it an attractive candidate for partnerships or acquisition.
Investors should closely watch the upcoming data releases, as positive news could catalyze further growth in the stock price. Moreover, SELLAS' solid strategic positioning within oncology creates a competitive edge amid a booming market for innovative cancer treatments.
However, potential investors should also consider the inherent risks associated with biopharmaceutical investments, especially those related to clinical trials and regulatory approvals. As the company progresses, it may face challenges that could impact its stock performance.
In summary, SELLAS Life Sciences represents a compelling investment opportunity given its recent index inclusion and robust pipeline, balanced by the necessary caution of inherent risks in the biopharmaceutical landscape. Investors should adopt a watchful approach as they evaluate the company’s next steps in the market.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Company will be added to the Russell 3000 ® and Russell 2000 ® Indexes, effective after the U.S. market close on June 27, as part of the 2025 Russell indexes annual reconstitution.
The Russell 3000 ® Index tracks the performance of the largest 3,000 publicly traded U.S. companies and serves as a broad benchmark for the U.S. equity market. The Russell 2000 ® Index, a subset of the Russell 3000 ® , measures the performance of the small-cap stocks and represents approximately 10% of the total market capitalization of the U.S. equity market.
Membership in the indexes lasts for one year and results in automatic inclusion in appropriate growth and value style indexes. The Russell indexes are used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.
“Being added to the Russell 3000 ® and Russell 2000 ® Indexes marks an important corporate milestone for SELLAS and reflects the strong progress we continue to make advancing our pipeline and building long-term shareholder value,” said John Burns, Senior Vice President and Chief Financial Officer of SELLAS. “Inclusion in these indexes increases our visibility with institutional investors as we approach the readout of full topline Phase 2 data of SLS009 in acute myeloid leukemia (AML) and the final analysis of our Phase 3 pivotal REGAL trial of GPS in AML.”
For further information on the Russell 3000 ® and Russell 2000 ® Indexes and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website .
About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit www.sellaslifesciences.com .
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,” “should,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend,” or “continue” and other words or terms of similar meaning. These statements include, without limitation, statements related to the GPS clinical development program, including the REGAL study and the timing of future milestones related thereto. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 20, 2025 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made.
Investor Contact
John Fraunces
Managing Director
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com
FAQ**
How might the inclusion of SELLAS Life Sciences Group Inc. SLS in the Russell 3000 ® and Russell 2000 ® Indexes impact its stock liquidity and visibility among institutional investors?
What are the key milestones expected from SELLAS Life Sciences Group Inc. SLS regarding the Phase 2 data readout for SLS009 in acute myeloid leukemia (AML)?
Considering the competitive landscape in oncology, how does SELLAS Life Sciences Group Inc. SLS plan to differentiate its products, especially GPS and SLS009, in terms of efficacy and safety?
What risks does SELLAS Life Sciences Group Inc. SLS foresee in the clinical development of its products, and how might these risks affect future funding or partnerships?
**MWN-AI FAQ is based on asking OpenAI questions about SELLAS Life Sciences Group Inc. (NASDAQ: SLS).
NASDAQ: SLS
SLS Trading
20.38% G/L:
$6.97 Last:
7,820,479 Volume:
$6.48 Open:
